GRCE
Grace Therapeutics, Inc.
Latest Form 4:Purchase$24KbyOpaleye Management Inc. (10% Owner) · filed Aug 19, 2026
Grace Therapeutics, Inc. (GRCE) has 1 SEC Form 4 filing (1 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Aug 19, 2026.
- Industry:Biotechnology
- CEO:Prashant Kohli
- Employees:5
- HQ:Princeton, NJ, US
- IPO:2012-02-07
Insider Buying
$24K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
Market Cap
$44.6M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| 10% Owner | Purchase | 11,608 | $24K | Aug 19 | SEC ↗ |
Related companies
Grace Therapeutics, Inc. is in the Healthcare sector.